Home Home >News >Updates

AstraZeneca sets up cell therapy operations in Lin-gang

en.lingang.gov.cn| Updated: 16, 2026 L M S

UK-based pharmaceutical company AstraZeneca announced the creation of a cell therapy subsidiary in the Lin-gang Special Area during the 9th China International Import Expo (CIIE), held in Shanghai from Nov 5 to 10.

The launch ceremony of AstraZeneca's booth at the 9th CIIE. [Photo/Shanghai Observer]

The move is expected to strengthen AstraZeneca's end-to-end cell therapy operations in China, from R&D to commercial production, while expanding its supply reach across the Asian market.

Earlier this year, the enterprise unveiled plans to invest more than 100 billion yuan ($15 billion) in China by 2030, aiming to expand its pharmaceutical manufacturing and R&D footprint.

Iskra Reic, AstraZeneca's international executive vice president, said China's leading scientific research strengths, advanced manufacturing capacity, and dynamic life sciences innovation ecosystem strengthen the company's confidence in its long-term commitment to the country.

The planned investment reflects this confidence and will further strengthen AstraZeneca's presence across China's pharmaceutical value chain, contribute to the vision of building a Healthy China by 2035, and bring more innovative treatments to patients worldwide, Reic added.

  • Address No 200 Shengang Avenue, Pudong New Area, Shanghai, China
  • Zip Code 201306
  • TEL +86-21-68283063
  • FAX +86-21-68283000
top